Smyth, David
Zhang, Liyong https://orcid.org/0000-0002-7498-6496
Al-Khalaf, Mohammad
Robichaud, Sabrina
Seymour, Richard
Geoffrion, Michele
Jung, Richard
Parlow, Simon
Du, Feng https://orcid.org/0000-0002-8489-742X
McNeill, Brian
Du, Qiujiang
Beauregard, Caroline
Zhao, Xiaoling
Ouimet, Mireille
Beug, Shawn T. https://orcid.org/0000-0002-9991-3306
LaCasse, Eric C.
Rayner, Katey J. https://orcid.org/0000-0001-6230-426X
Mak, Tak W.
Hibbert, Benjamin https://orcid.org/0000-0003-0906-1363
Korneluk, Robert G.
Liu, Peter P. https://orcid.org/0000-0002-3017-1199
Funding for this research was provided by:
Genome Canada
Heart and Stroke Foundation of Canada
Article History
Received: 5 January 2024
Accepted: 28 January 2026
First Online: 12 March 2026
Competing interests
: E.C.L. is a co-founder and the Chief Scientific Officer of Protaxis Therapeutics, Inc. All other authors report no competing interests.